USA Health Homepage

Navigation

Felicia Wilson

Felicia L. Wilson, M.D.

Pediatric Hematologist/OncologistProfessor of PediatricsSpecialty: Pediatrics, Cancer Care
Refer a Patient
Request an Appointment
Or call to make an appointment1 (251) 410-5437

Board Certifications

  • American Board of Pediatrics (Pediatric Hematology-Oncology)

Education

  • Medical School: Medical University of South Carolina College of Medicine | Charleston, SC
  • Residency: Greenville Hospital System | Greenville, SC
  • Fellowship: Emory University of Medicine | Atlanta, GA

Languages

  • English

Locations

Clinical Trials

18-042 - Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic LeukemiaStatus: open

AAML1331 A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid - A COG Groupwide Phase III Study

Treatment for Acute Myeloid Leukemia | Pediatric Oncology

Children's & Women's Hospital
1700 Center Street
Mobile, Alabama 36604
Learn More
(251) 445-9834
18-006 - Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell TumorsStatus: open

AGCT1531 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Treatment for Germ Cell Tumor (GCT)

Children's & Women's Hospital
1700 Center Street
Mobile, Alabama 36604
Learn More
(251) 445-9834
18-260 - ARST1431 - Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk RhabdomyosarcomaStatus: open

ARST1431 A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Treatment for Pediatric Oncology- Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Mitchell Cancer Institute
1660 SpringHill Avenue
Mobile, Alabama 36604
Learn More
(251) 445-9834
19-256 - AALL1731 - A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL TherapyStatus: open

AALL1731 A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

Treatment for Pediatric Oncology- Localized B-Lymphoblastic Lymphoma (B-LLy)

Mitchell Cancer Institute
1660 SpringHill Avenue
Mobile, Alabama 36604
Learn More
(251) 445-9834
19-452 - AALL1732 - Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyStatus: open

AALL1731 A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

Treatment for Pediatric Oncology- Localized B-Lymphoblastic Lymphoma (B-LLy)

Pediatrics Complex Care Clinic
1601 Center Street
Suite 1A
Mobile, Alabama 36604
Learn More
(251) 445-9834
17-411 - Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene RearrangementStatus: open

AALL15P1: A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND#TBD, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A Gene Rearrangement

Treatment for Pediatric Oncology - Acute Lymphoblastic Leukemia

Children's & Women's Hospital
1700 Center Street
Mobile, Alabama 36604
Learn More
(251) 445-9834
This link will open in a new tab or window.